EU pharma wants legal clarity on post-authorization efficacy studies
This article was originally published in SRA
Most EU pharmaceutical sector stakeholders believe that the European Commission should issue a delegated act that clarifies when post-authorization efficacy studies (PAESs) may be required under the pharmacovigilance legislation1,2.
You may also be interested in...
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.